<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5856">
  <stage>Registered</stage>
  <submitdate>28/03/2016</submitdate>
  <approvaldate>28/03/2016</approvaldate>
  <nctid>NCT02725268</nctid>
  <trial_identification>
    <studytitle>Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer</studytitle>
    <scientifictitle>A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Ka Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>U1111-1168-1824</secondaryid>
    <secondaryid>C31004</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Endometrial Neoplasms</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Womb (Uterine or endometrial cancer)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Paclitaxel
Treatment: drugs - MLN0128
Treatment: drugs - MLN1117

Experimental: Paclitaxel 80 mg/m^2 - Paclitaxel 80 mg/m^2, IV, weekly on Days 1, 8, and 15 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent.

Experimental: Paclitaxel 80 mg/m^2 + MLN0128 4 mg - Paclitaxel 80 mg/m^2, IV, weekly on Days 1, 8, and 15 of a 28-day cycle along with MLN0128 4 mg, capsule, orally on Days 2-4, 9-11, 16-18, and 23-25 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent.

Experimental: MLN0128 30 mg - MLN0128 30 mg, capsule, orally, once weekly on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent.

Experimental: MLN0128 4 mg + MLN1117 200 mg - MLN0128 4 mg, capsule, orally and MLN1117 200 mg, capsule, orally on Days 1-3, 8-10, 15-17, and 22-24 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent.


Treatment: drugs: Paclitaxel
Paclitaxel intravenous solution

Treatment: drugs: MLN0128
MLN0128 capsules

Treatment: drugs: MLN1117
MLN1117 capsules

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression Free Survival (PFS) - PFS is defined as the time from the date of randomization to the date of first documentation of progressive disease or death due to any cause, whichever occurs first. For a participant who has not progressed and is last known to be alive, PFS will be censored at the last response assessment that is stable disease (SD) or better.</outcome>
      <timepoint>Up to 30 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants who Experience at Least One Treatment-emergent Adverse Event (TEAE)</outcome>
      <timepoint>From the first dose of study drug through 30 days after the last dose of study drug (Up to 30 Months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS) - OS is defined as the time from the date of randomization to the date of death. Participants without documentation of death at the time of analysis will be censored at the date last known to be alive.</outcome>
      <timepoint>Up to 30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Progression (TTP) - TTP is defined as the time from the date of randomization to the date of first documentation of progression. For a participant who has not progressed, TTP will be censored at the last response assessment that is stable disease (SD) or better.</outcome>
      <timepoint>Up to 30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Response Rate (ORR) - ORR is defined as the percentage of participants who achieve a best response of a complete response (CR) or partial response (PR) using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.</outcome>
      <timepoint>Up to 30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Benefit Rate (CBR) - CBR is defined as the percentage of participants with complete response (CR) or partial response (PR) or stable disease (SD).</outcome>
      <timepoint>Up to 30 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Benefit Rate (CBR) at Week 16 (CBR-16) - CBR-16 is defined as the percentage of participants who achieve CR or PR of any duration or have SD with a duration of at least 16 weeks.</outcome>
      <timepoint>Up to 30 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Histologic or cytologic diagnosis of endometrial carcinoma (including endometrioid,
             serous, mixed adenocarcinoma, clear-cell carcinoma, or carcinosarcoma).

          2. Evidence that the endometrial cancer is advanced, recurrent, or persistent and has
             relapsed or is refractory to curative therapy or established treatments.

          3. At least 1 prior platinum-based chemotherapeutic regimen, but not more than 2 prior
             chemotherapeutic regimens, for management of endometrial carcinoma. Prior treatment
             may include chemotherapy, chemotherapy/radiation therapy, and/or
             consolidation/maintenance therapy. Chemotherapy administered in conjunction with
             primary radiation as a radio-sensitized therapy will be considered a systemic
             chemotherapy regimen.

          4. Measureable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,
             defined as at least 1 lesion that can be accurately measured in at least 1 dimension
             (longest diameter to be recorded). Each lesion must be = 10 mm in long axis when
             measured by computed tomography (CT), magnetic resonance imaging (MRI), or caliper
             measurement by clinical exam. Lymph nodes must be = 15 mm in short axis when measured
             by CT or MRI.

          5. Tumor accessible and patient consents to undergo fresh tumor biopsies.

          6. Female patients 18 years or older.

          7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          8. Female patients who:

               -  Are postmenopausal for at least 1 year before the screening visit, OR

               -  Are surgically sterile, OR

               -  If they are of childbearing potential, agree to practice 1 highly effective
                  method of contraception and 1 additional effective (barrier) method at the same
                  time, from the time of signing the informed consent through 90 days (or longer,
                  as mandated by local labeling [eg, United States Prescribing Information (USPI),
                  Summary of Product Characteristics (SmPC), etc.]) after the last dose of study
                  drug, OR

               -  Agree to practice true abstinence, when this is in line with the preferred and
                  usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation,
                  symptothermal, postovulation methods], withdrawal, spermicides only, and
                  lactational amenorrhea are not acceptable methods of contraception. Female and
                  male condoms should not be used together.)

          9. Clinical laboratory values as specified below within 4 weeks before the first dose of
             study drug:

               -  Bone marrow reserve consistent with absolute neutrophil count (ANC) = 1500/µL;
                  platelet count = 100,000/µL; hemoglobin A1c (HbA1c) &lt; 6.5%.

               -  Total bilirubin must be = 1.5 x the upper limit of normal (ULN).

               -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) must be = 2.5
                  x the upper limit of the normal range. AST and ALT may be elevated up to 5 times
                  the ULN if their elevation can be reasonably ascribed to the presence of
                  metastatic disease in liver.

               -  Creatinine clearance = 50 mL/min/1.73 m^2 based either on Cockcroft-Gault
                  estimate or based on a 12- or 24-hour urine collection.

               -  Fasting serum glucose &lt; 130 mg/dL and fasting triglycerides = 300 mg/dL.

         10. Ability to swallow oral medications, willingness to perform mucositis prophylaxis, and
             suitable venous access for the study-required blood sampling.

         11. Voluntary written consent must be given before performance of any study-related
             procedure not part of standard medical care, with the understanding that consent may
             be withdrawn by the patient at any time without prejudice to future medical care.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Previous treatment with any weekly taxane regimen.

          2. Previous treatment with phosphoinositide 3-kinase (PI3K), serine/threonine-specific
             protein kinase (AKT), dual PI3K/ mammalian (or mechanistic) target of rapamycin (mTOR)
             inhibitors, target of rapamycin complex 1/2 (TORC1/2) inhibitors or TORC1 inhibitors.

          3. Treatment with strong inhibitors and/or inducers of cytochrome P450 3A4 (CYP3A4),
             CYP2C9, or CYP2C19 within 1 week preceding the first dose of study drug.

          4. Initiation of treatment with hematopoietic growth factors, transfusions of blood and
             blood products, or systemic corticosteroids (either intravenous (IV) or oral steroids,
             excluding inhalers) within 1 week before administration of the first dose of study
             drug (patients already receiving erythropoietin on a chronic basis for = 4 weeks are
             eligible).

          5. Is taking proton pump inhibitors (PPIs) within 7 days of the first dose of study drug
             or who require treatment with PPIs throughout the trial or those who are taking H2
             receptor antagonists within 24 hours of the first dose of study drug.

          6. A prothrombin time (PT) or activated partial thromboplastin time (aPTT) above the ULN
             or a history of a coagulopathy or bleeding disorder.

          7. Sensory or motor neuropathy = Grade 2.

          8. Central nervous system (CNS) metastasis, endometrial leiomyosarcoma, or endometrial
             stromal sarcoma.

          9. Manifestations of malabsorption due to prior gastrointestinal surgery,
             gastrointestinal disease, or for some other reason that may alter the absorption of
             MLN0128 or MLN1117. In addition, patients with enteric stomata are also excluded.

         10. Other clinically significant co-morbidities, such as uncontrolled pulmonary disease,
             active CNS disease, active infection, or any other condition that could compromise
             participation of the patient in the study.

         11. Known human immunodeficiency virus infection.

         12. History of any of the following within the last 6 months before administration of the
             first dose of study drug:

               -  Ischemic myocardial event, including angina requiring therapy and artery
                  revascularization procedures.

               -  Ischemic cerebrovascular event, including transient ischemic attack and artery
                  revascularization procedures.

               -  Requirement for inotropic support (excluding digoxin) or serious (uncontrolled)
                  cardiac arrhythmia (including atrial flutter/fibrillation, ventricular
                  fibrillation, or ventricular tachycardia).

               -  Placement of a pacemaker for control of rhythm.

               -  New York Heart Association Class III or IV heart failure.

               -  Pulmonary embolism.

         13. Significant active cardiovascular or pulmonary disease before administration of the
             first dose of study drug, including:

               -  Uncontrolled hypertension (ie, either systolic blood pressure &gt; 180 mm Hg or
                  diastolic blood pressure &gt; 95 mm Hg).

               -  Pulmonary hypertension.

               -  Uncontrolled asthma or oxygen saturation &lt; 90% by arterial blood gas analysis or
                  pulse oximetry on room air.

               -  Significant valvular disease; severe regurgitation or stenosis by imaging
                  independent of symptom control with medical intervention; or history of valve
                  replacement.

               -  Medically significant (symptomatic) bradycardia.

               -  History of arrhythmia requiring an implantable cardiac defibrillator.

               -  Baseline prolongation of the rate-corrected QT interval (QTc; eg, repeated
                  demonstration of QTc interval &gt; 480 ms, or history of congenital long QT
                  syndrome, or torsades de pointes).

         14. Diagnosed or treated for another malignancy within 2 years before administration of
             the first dose of study drug or previously diagnosed with another malignancy and have
             any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma
             in situ of any type are not excluded if they have undergone complete resection.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>260</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/08/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>St George Hospital - Kogarah</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Herston</hospital>
    <hospital>Monash Medical Centre Clayton - Clayton</hospital>
    <hospital>Sunshine Hospital - Footscray</hospital>
    <hospital>Cabrini Hospital Malvern - Malvern</hospital>
    <hospital>Peter MacCallum Cancer Centre-East Melbourne - Melbourne</hospital>
    <postcode>2217 - Kogarah</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3011 - Footscray</postcode>
    <postcode>3144 - Malvern</postcode>
    <postcode>3000 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Wilrijk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mecklenburg Vorpommern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Niedersachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Schleswig Holstein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Forli - Cesena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Brescia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ravenna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Bergen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Stavanger</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Avon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Devon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Surrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Millennium Pharmaceuticals, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>European Network of Translational Research in Ovarian Cancer - EUTROC</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>European Network of Individualized Treatment in Endometrial Cancer - ENITEC</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study is to determine if MLN0128 in combination with weekly
      paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02725268</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Monitor</name>
      <address>Millennium Pharmaceuticals, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Takeda Study Registration Call Center</name>
      <address />
      <phone>+1-844-662-8532</phone>
      <fax />
      <email>GlobalOncologyMedinfo@takeda.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>